Table 4.
Mean differences from estimated marginal means of final multilevel models examining activity session outcomes.
| Predictor | MD | 95% CI | p |
|---|---|---|---|
| PHQ-4 | |||
| Time (pre- to postsession) | −0.75 | [−1.01, −0.49] | <0.001 |
| Day | −0.11 | [−0.28, 0.06] | 0.193 |
| Time × Day | −0.02 | [−0.17, 0.13] | 0.797 |
| PTSD diagnosis | 0.99 | [0.44, 1.55] | 0.001 |
| Time × PTSD diagnosis | 0.01 | [−0.52, 0.55] | 0.961 |
| Pharmacotherapy | 1.00 | [0.48, 1.51] | <0.001 |
| Time × Pharmacotherapy | −0.64 | [−1.14, −0.14] | 0.012 |
| PAS | |||
| Time (pre- to postsession) | 2.71 | [1.35, 4.06] | <0.001 |
| Day | 0.43 | [−0.48, 1.35] | 0.348 |
| Time × Day | −0.02 | [−0.71, 0.67] | 0.947 |
| PTSD diagnosis | −0.68 | [−3.29, 1.94] | 0.612 |
| Time × PTSD diagnosis | 0.46 | [−2.02, 2.93] | 0.714 |
| Pharmacotherapy | −2.21 | [−4.63, 0.21] | 0.073 |
| Time × Pharmacotherapy | 3.04 | [0.76, 5.33] | 0.010 |
MD, mean difference; CI, confidence interval; PHQ-4, 4-item Patient Health Questionnaire; PTSD, posttraumatic stress disorder; PAS, Positive Affect Schedule. Bolding indicates statistical significance. Postsession is the comparator for the time variable MDs; positive probable PTSD diagnosis is the comparator for the PTSD diagnosis; concurrent pharmacotherapy is the comparator for the Pharmacotherapy MDs.